Investing.com — CG肿瘤学 (CG Oncology)股价跌至52周低点23.9美元，仅在过去一周就下跌了11%。根据 InvestingPro 数据显示，这比该股52周高点47美元有显著下跌。这家专注于开发癌症免疫疗法的公司在过去一年中股价大幅回落，跌幅高达42.73%。尽管出现抛售，分析师仍维持乐观的价格目标，范围从55美元到82美元不等，且公司保持稳健的财务状况，现金多于债务 ...

CG Oncology, Inc. (CGON) closed the last trading session at $26.42, gaining 2.2% over the past four weeks, but there could be ...

In a report released today, Sean Laaman from Morgan Stanley maintained a Buy rating on CG Oncology, Inc. (CGON – Research Report), with a price ...

鉴于即将发布的数据和cretostimogene与TAR-200之间的比较分析，H.C. Wainwright重申了对CG Oncology股票的买入评级和75美元的目标价。该公司保持强劲的财务状况，当前比率为35.3，值得注意的是，其持有的现金多于债务，为其临床开发项目提供了财务灵活性。随着下一次财报预计于2025年5月8日发布，投资者可以通过 InvestingPro ...

We recently published a list of the 12 Best IPO Stocks to Buy in 2025. In this article, we are going to take a look at where ...

Durability Results from BOND-003 data will be presented as a late breaker as part of AUA’s Practice-changing, Paradigm-shifting Clinical Trials ...

Full Year 2024 Results Key Financial Results Net loss: US$88.0m (loss widened by 30% ...

March 28, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing ...

March 28, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing ...

Across the recent three months, 4 analysts have shared their insights on CG Oncology CGON -2.73% Get Free Report , expressing a variety of opinions spanning from bullish to bearish. Summarizing their ...

Across the recent three months, 4 analysts have shared their insights on CG Oncology (NASDAQ:CGON), expressing a variety of opinions spanning from bullish to bearish. Summarizing their recent ...